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subjected (range 31.4% in US −38.1% in France, p = 0.827) reported having a NSHE 
at least weekly. Diabetes management was impacted as 20.9% of insulin dependent 
subjects reported decreasing their normal insulin dose on average 18.7 units per day 
over 3.2 days. Further, a mean of 7.0 extra blood glucose tests were conducted in the 
week following their last NSHE. For those whose last NSHE was at work (n = 483), 
work productivity was impacted with 28.6% reported missing work (e.g., leaving 
early) due to this NSHE. For those whose last NSHE occurred during the day but 
outside of work (n = 368), 18.2% of respondents reported work absenteeism due to 
this NSHE. For those whose last NSHE was during sleep (n = 121), 16.5% of respond-
ents reported subsequent work absenteeism. CONCLUSIONS: NSHE’s have a con-
siderable impact on work loss productivity across these countries. The seriousness of 
NSHEs may be underestimated and should be considered an important part of diabetes 
management.
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OBJECTIVES: Weight management and exercise are key self-management treatments 
for patients with type 2 diabetes mellitus (T2DM). This study examined the associa-
tion between trying to lose weight or exercising regularly and health-related quality 
of life among individuals with and without T2DM. METHODS: Respondents to the 
US Study to Help Improve Early evaluation and management of risk factors Leading 
to Diabetes (SHIELD) baseline survey reported if they had tried to lose weight during 
the last 12 months and if they currently exercised regularly for > 6 months. Respond-
ents also completed the SF-12 quality-of-life survey 1 year later. The Physical Com-
ponent Score (PCS) and Mental Component Score (MCS) of the SF-12 were computed, 
and differences between T2DM respondents (n = 2419) and respondents with no 
diabetes mellitus (n = 6750) were tested using t-tests. Linear regression models adjusted 
for age, gender, race, education, household income, body mass index (BMI), and 
diabetes status. RESULTS: Among T2DM respondents, 71% reported trying to lose 
weight in the past 12 months and 20% reported exercising regularly for >6 months, 
compared with 64% of respondents without diabetes reporting trying to lose weight 
and 25% exercising regularly. After adjusting for demographics, BMI and diabetes 
status, trying to lose weight was not associated with higher PCS scores (p = 0.87), but 
was independently associated with higher MCS scores (p = 0.01) in the subsequent 
year. After adjustment, exercising regularly was signiﬁcantly associated with higher 
subsequent PCS and MCS scores (p < 0.001). CONCLUSIONS: Respondents with 
T2DM who reported exercising regularly had signiﬁcantly better physical quality of 
life, compared with respondents without diabetes who exercised regularly. Respond-
ents with T2DM who reported trying to lose weight or exercising regularly for > 6 
months had better mental quality of life, compared with respondents without diabetes 
who tried to lose weight or exercised.
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OBJECTIVES: Hypoglycemia can be a critical issue in T2DM management and may 
impact patients in many ways. Using published data we aimed to identify and evaluate 
the impact of these events on patient quality of life and treatment satisfaction. 
METHODS: A systematic review of literature databases (no date limit, 1066 citations 
retrieved) and conference proceedings (2007–2009) was carried out. Studies reporting 
the effect of hypoglycemic events on quality of life or treatment satisfaction using 
generic or hypoglycemia-speciﬁc measures were included. RESULTS: Seventeen studies 
were identiﬁed that provided useful information for the study question, mostly in 
European populations. All studies relied on self-reporting of hypoglycemic episodes, 
with heterogeneity in methods and classiﬁcation used. Seven of eight studies reported 
negative correlations between reporting (and in three studies also severity) of hypogly-
cemic events and QoL measured using the EQ-5D instrument: the difference between 
patients reporting and not reporting events (summary score: 0.08–0.20 on 0–1 scale; 
VAS: 4.2–11.3 on 0–100 scale) suggests clinical importance. No correlation was 
observed in the sole study examining insulin-treated patients. Four additional studies 
reported correlations between experience of hypoglycemia and lower QoL scores using 
other generic instruments; three studies reported lower scores on the Treatment Sat-
isfaction Questionnaire for Medication in oral antidiabetics (OAD)-treated patients 
experiencing hypoglycemia. The results of three studies indicated that occurrence and 
severity of hypoglycemia were associated with higher Worry scores in the Hypoglyc-
emia Fear Survey-II in OAD-treated patients, with one study further identifying this 
as a clinically important difference when related to treatment satisfaction. CONCLU-
SIONS: This review identiﬁes a body of data which describe the relationship between 
hypoglycemia and patient-reported outcomes. Despite variation in methods and 
instruments used, the results of these studies indicate hypoglycemic events have a 
notable and clinically important impact on quality of life in T2DM patients, including 
those treated with OADs.
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OBJECTIVES: A central Texas HMO plan implemented a pharmacist-led diabetes 
medication management program (MMP) offering co-pay waivers. Medication adher-
ence and diabetic control were compared between patients enrolled in the MMP vs. 
control patients. Health care costs and utilization were also compared. METHODS: 
Patients were enrolled in the MMP if they had baseline A1C levels >7.5% and continu-
ous enrollment throughout the study period (“rolling” enrollment from August 
2006-July 2008). The enrollees and controls were matched 1:1 by age, gender, baseline 
A1C, and Charlson comorbidity index (CCI). A1C and adherence (Medication 
Possession Ratio (MPR)) were measured one year before and after implementation. 
Paired t-tests compared the changes in MPR and A1C. Health care costs and 
utilization were analyzed by year, group, types of service, and diabetes-related vs. 
all-cause claims. RESULTS: A total of 136 patients were enrolled in the MMP for at 
least 1 year (46 of those enrolled for two years). A1C decreased 5% in controls and 
12% in MMP patients; the difference between groups was statistically signiﬁcant (P 
< 0.001). The MPR for oral hypoglycemics increased from 76% to 81% one year after 
in MMP enrollees, whereas MPR remained at 76% in controls; the difference was not 
statistically signiﬁcant (P = 0.159). The baseline health care costs were 23% higher in 
MMP enrollees than controls, possibly due to a few outliers. After one year, the 
average per member per month (PMPM) cost increased by 21% and 14% in MMP 
and control groups, respectively; the larger increase was mainly attributable to growth 
in diabetes-related drug and outpatient claims. Over two years post-implementation, 
the average MMP PMPM increased by 2%, while the average control PMPM 
increased by 14%. CONCLUSIONS: The medication management program improved 
patients’ outcomes. Although one-year costs increased, the slowdown of costs over 2 
years in MMP patients compared to controls indicates potential savings over the long 
term.
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OBJECTIVES: To increase our understanding of the impact of diabetes-related non-
severe hypoglycemic episodes (NSHE’s) on patient functioning and diabetes manage-
ment. METHODS: A web-based survey of adults with diabetes (US, France, Germany, 
and UK). NSHE’s were classiﬁed as occurring in the past month, either during the day 
or during sleep (nocturnal). RESULTS: 6,756 persons with diabetes were surveyed, 
2,430 had at least one NSHE in the past month. The mean age was 46.1 ± 14.8 (range 
18–90), 1378 (56.7%) were female and average duration of diabetes was 12.8 ± 11.8 
years (range 0.08–72.8). 89.2% (n = 2,167) reported at least 1 daytime NSHE and 
44.7% (n = 1086) had at least 1 nocturnal NSHE. In the past month, $45.64 out-of-
pocket was spent on foods, glucose products, transportation, etc. to either prevent or 
cope with these NSHE’s. For daytime NSHE’s, the average amount of time respond-
ents reported not functioning at their usual level was 9.0 ± 24.9 hours if the NSHE 
occurred while they were active and 12.4 ± 62.3 hours for NSHE occurring while not 
active. On average, 8.3 extra blood glucose monitoring test strips were used and 
insulin was decreased on average by 10 units over the following 6 days. For sleep 
related NSHE’s, on average, it took 1.4 ± 1.9 hours to return to sleep with 15.6% 
not being able to go back to sleep at all after the episode. 81.9% (n = 889) reported 
being tired the following day as a result of the event. Sleep related NSHE’s resulted 
in on average 11.4 ± 84.1 extra blood glucose monitoring test strips used and insulin 
was decreased on average by 13.8 units over the following 6 days. CONCLUSIONS: 
NSHE have a considerable impact on daily functioning as well as add to the ﬁnancial 
burden of living with diabetes. The seriousness of NSHE’s may be underestimated and 
should be considered an important part of diabetes management.
PDB56
RELATIONSHIP BETWEEN CARE FINANCING STRUCTURE AND 
DIABETES CARE ASSESSMENTS AMONG MEDICAID BENEFICIARIES 
WITH TYPE 2 DIABETES
Phattarabenjapol S1, Plake KS2, Modi A2, Carney Doebbeling C3, Thomas J2
1Ubon Ratchathani University, Warin Chamrab, Ubon Ratchathani, Thailand, 2Purdue 
University, West Lafayette, IN, USA, 3Ofﬁce of Medicaid Policy and Planning, Indianapolis, 
IN, USA
OBJECTIVES: We estimated rates of diabetes care indicated services in adult type 2 
diabetics in a state Medicaid population and associations between receipt of services 
in Fee-For-Service (FFS); Care Management (CM), i.e., fee-for-service plus care coor-
dination; and Managed Care (MC) subprograms. METHODS: A retrospective cohort 
analysis of Indiana Medicaid 2006 and 2007 eligibility, claims, and encounter ﬁles 
was conducted. Persons 18 to 64 y/o, with diabetes based on ICD-9 codes or NDC 
codes, and ≥12 months continuous eligibility in one subprogram were included. Exclu-
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sions included no evidence of a diabetes diagnosis prior to study intervals or death 
prior to the end of intervals. Indicated services based on ADA guidelines for lipid (LI) 
, retina examinations (RE), microalbuminuria (MA), serum creatinine (SC), inﬂuenza 
vaccinations (FV), and A1c tests were identiﬁed from CPT codes and HCPCS codes 
(≥ 2 annually for A1c tests and ≥1 annually for other tests). Logistic regression assessed 
associations between subprogram and assessments controlling for age, gender, ethnic-
ity, comorbidity, and state region. RESULTS: A sample of 22,017 persons, with 57% 
FFS, 26% CM and 17% MC was identiﬁed. Overall, proportions (95% C.I.) meeting 
recommendations were 63.5%, (62.9 – 64.1) SC, 37.2% (36.5 – 37.8) LI, 30.5% (29.9 
– 31.1) RE, 23.3% (22.8 – 23.9) MA, 18.2% (17.6 – 18.7) FV, and 15.6% (15.1 – 
16.1) A1c tests. Compared to FFS, odds ratios ranged from 1.38 for RE to 4.74 for 
LI under CM and excluding RE which did not differ, 1.39 for FV to 3.78 for LI under 
MC (P ≤ 0.001 for all). CONCLUSIONS: While A1c rates are likely low due to low 
claims submission for point of service A1c tests, other rates are likely representative. 
Associations between subprograms and assessments may indicate strategies such as 
chronic disease management and primary care coordination may be effective in 
increasing diabetes care assessments.
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OBJECTIVES: To examine the effect of an employer sponsored, community phar-
macy based medication therapy management program (MTM) on clinical outcomes 
in patients with diabetes. METHODS: A one year prospective, pre-post longitudinal 
study. Study Participants were employees and dependents of the City of Toledo in 
Ohio who received care at local independent pharmacies and were seen every three 
months. Enrolled participants had diabetes and/or other comorbid conditions. Data 
collected: clinical (A1c, blood pressure, BMI), social (caffeine and alcohol intake, 
exercise and smoking habits, etc.), process measures (podiatrist, ophthalmologist, 
and dentist visits). Data was analyzed using SPSS v. 16.0. Descriptive statistics and 
Friedman tests were used. Data was analyzed for baseline, 6 months, and 12 months. 
RESULTS: One hundred and one patients enrolled at baseline. Mean A1c improved 
from 7.77 to 7.5 (p = 0.866). Patients with uncontrolled A1c at baseline improved 
from a mean of 8.87 to 8.18 (p = 0.247) at baseline and 12 months. Systolic blood 
pressure improved from 136.17 mmHg to 130.57 mmHg (p = 0.189) and signiﬁ-
cantly improved for patients with baseline SBP ≥ 140 mmHg (p < 0.001). Diastolic 
blood pressure improved from 84.4 mmHg to 80.2 mmHg (p = 0.252) and signiﬁ-
cantly improved for patients with baseline DBP ≥ 90 mmHg (p < 0.001). Social 
measures showed a 34.15% decrease in caffeine intake and 44.12% increase in 
exercise habits. There was a 35.90% increase in podiatrist visits, a 13.51% increase 
in dental visits, and a 29.73% increase in ophthalmologist visits. Use of sick days 
decreased from 1.12 ± 5.32 days per 3 months to 0.09 ± 0.39 (p = 0.368). CON-
CLUSIONS: This community pharmacy MTM program has shown improved out-
comes for patients who participated in pharmacist-guided interventions over a one 
year time period.
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OBJECTIVES: Opioids have commonly been used to treat chronic pain conditions, 
including diabetic peripheral neuropathic pain (DPNP), but tolerance issues have 
limited their use by providers. Newer classes of drugs are now approved for DPNP 
therapy, but no published data currently exists that assess changes in the utilization 
of opioid therapy following treatment with these newer agents. This study compared 
the use of opioids between DPNP patients who initiated treatment with duloxetine 
versus other standard of care (SOC) DPNP treatments. METHODS: This retrospective 
cohort study assessed commercially-insured DPNP patients aged 18 to 64 over a 1-year 
follow-up period who initiated treatment with either duloxetine or other SOC treat-
ments (tricyclic, venlafaxine, gabapentin, pregabalin) between March 1,2005 and 
December 31, 2005. Initiation was deﬁned as a 90-day period without available study 
medication. Dispense date of the ﬁrst study medication initiation was denoted as the 
index date. Selected patients had 12 months continuous enrollment before and after 
the index date, and no opioid pill coverage during the 90 days prior to initiation. 
Patients were matched to duloxetine-treated patients via propensity scoring, control-
ling for demographics, comorbidities, prior health care utilization and costs, and 
medication history. RESULTS: The matched sample included 117 patients in each of 
the duloxetine and SOC cohorts. Compared with SOC patients, duloxetine-treated 
patients were less likely to use any opioids (52.1% vs. 84.6%, p < 0.05) over the 
12-month post-index period. Duloxetine-treated patients, on average, had 2 fewer 
opioid prescriptions dispensed, 27 fewer days on opioids, 120 days greater delay in 
subsequent opioid use, and 1816mg lower morphine equivalent dosage than SOC 
patients (all p < 0.05). Also, duloxetine-treated patients had signiﬁcantly lower total 
($18,623 vs. $30,602, p < 0.05) and outpatient costs ($7,371 vs. $15,343, p < 0.05). 
CONCLUSIONS: Duloxetine treatment is associated with deferred and reduced 
opioid use among DPNP patients. Patients initiated on duloxetine also had lower 
health care costs.
PDB60
GAPS IN MEDICAID COVERAGE AND THE RISK FOR HOSPITALIZATION 
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OBJECTIVES: The objective of this study was to evaluate whether Medicaid coverage 
gap is associated with higher risks for diabetes-speciﬁc hospitalizations and all-cause 
mortality among working-aged adults (i.e., those aged 19–64 years) with diabetes. 
METHODS: Using administrative claims data, we conducted a retrospective cohort 
study of working-aged adults with diabetes and who were enrolled in a state Medicaid 
program. Coverage gap was deﬁned as at least one month interruption in their Med-
icaid enrollment from January 2002 to December 2003. The primary outcomes of 
interest were diabetes-speciﬁc hospitalization and all-cause mortality during follow-up 
(January to December 2004). Multivariate regression analyses were performed to 
assess the independent association between adherence to statin and outcome measures. 
Key confounding variables include age, gender, race, comorbidities (measured using 
Charlson Comorbidity Index), prior hospitalization due to diabetes, and use of medi-
cations essential to diabetes management including oral hypoglycemic agents, insulin, 
antihypertensive agents, and statins. RESULTS: A total 24,996 patients were included 
in the study. Mean age 50.2 ± 10.3 years, 29.7% male, 70.3 female; 30.3% white, 
59.3% black. About 86% had continuous Medicaid coverage and 14% had at least 
one month gap in their Medicaid coverage. During follow-up, those with at least 
one-month in their coverage were 16.2% less likely (OR: 0.838; 95%CI: 0.714–0.985) 
to have diabetes-speciﬁc hospital admissions and 44.9% less likely (OR: 0.551; 
95%CI: 0.430–0.706) to have all-cause mortality during the follow up period. CON-
CLUSIONS: The results from this study suggest that gaps in Medicaid coverage are 
not associated with higher risks for diabetes-speciﬁc hospitalizations and all-cause 
mortality in the follow up period. However, the study lacked information on why 
coverage gaps occurred and whether individuals with coverage gaps transitioned to 
other insurance coverage.
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OBJECTIVES: To examine racial and ethnic disparities in quality of health care 
(receipt of diabetes services, timeliness, and patient centeredness) among adults with 
diabetes in the U.S. in the years of 2005 and 2006. METHODS: The 2005 and 
2006 Medical Expenditure Panel Survey (MEPS) full-year consolidated data ﬁles 
including the Diabetes Care Survey and the Self-Administered Questionnaire were 
combined and analyzed. The racial and ethnic disparities in receipt of recommended 
diabetes services (A1C test, foot exam, eye exam, lipid proﬁle, and inﬂuenza immu-
nization), timeliness, and patient centeredness were examined. Chi-square test and 
logistic regression were conducted to evaluate the disparities before and after control-
ling for the confounding factors (age, gender, family income, education, health insur-
ance coverage, residential location, and language spoken most often at home). 
RESULTS: In 2005–2006, the racial and ethnic disparities in quality of health care 
among U.S. adults with diabetes still exist even after controlling for demographic 
and socioeconomic factors. African Americans and Hispanics were less likely to 
receive recommended diabetes services and patient-centered health care than Whites. 
African Americans had more foot examinations than Whites and Hispanics. There 
was no signiﬁcant difference in timeliness of health care among racial and ethnic 
groups. CONCLUSIONS: Racial and ethnic disparities in receipt of recommended 
diabetes services and patient centeredness of health care among adults with diabetes 
remained in the U.S. in 2005–2006. Age, family income, health insurance coverage, 
education, residential location, and English-speaking were correlated with racial and 
ethnic disparities. As this study is focused on disparities among only Whites, African 
Americans, and Hispanics, future studies comparing possible differences among other 
U.S. ethnic groups (e.g., American Indians or Alaska Natives) are needed using 
more-year, larger databases.
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OBJECTIVES: The objective of this study was to evaluate the main effect of health 
insurance plan type on health resource utilization (emergency room (ER) visit or 
hospital admission) in privately insured patients with Type 2 diabetes between the 
ages of 18 to 64 years. The outcomes of interest were the odds of an emergency room 
visit or a hospital admission associated in patients with Type 2 diabetes. METHODS: 
The data source was the 2000–2001 MarketScan database, which is comprised of 
administrative claims data for over 2.5 million privately insured individuals in the 
United States. The odds of an emergency room visit or hospital admission were evalu-
ated using multiple logistic regression models speciﬁed to control for demographic and 
clinical characteristics of the target patient population. A propensity score analysis 
using the stratiﬁcation approach was also done to further control for selection bias. 
RESULTS: After adjusting for the covariates, patients enrolled in FFS plans were 
